LL-37 dosing schedule
> Updated:
Human schedule
Controlled data on this compound are limited. The regimens below were gathered from public sources online (studies and protocols) and are given as a reference, not a usage plan.
LL-37 is an antimicrobial peptide that research and protocol sources administer subcutaneously (SubQ). The figures below are a generalized reference from published protocols, not a validated clinical dose.
This is a concise reference to regimens described for adults; it is not an individual prescription.
LL-37 dosing in the sources this page draws on is given as a range (100–400 mcg subcutaneously per day), not a fixed figure: the exact value in each protocol depends on cycle length and the specific research goal.
| Period / condition | Dose | Escalation |
|---|---|---|
| Start | 100 mcg subcutaneously, once daily | Starting dose |
| Maintenance | 100–300 mcg subcutaneously, once daily | Increase if needed |
| Upper range | up to 400 mcg subcutaneously per day; 4–12 week cycle | Maximum in this schedule |
The scientific context for this compound, from structure to published studies, is collected in the monograph.
Practical dosing and effect details
LL-37 is the C-terminal fragment of human cathelicidin hCAP18, and like most host-defense peptides, it is broken down quickly by serum and tissue proteases. That is a general pharmacological property of this class of molecules, not a finding from one specific clinical trial: a short circulating half-life in active form is the main reason research protocols favor daily subcutaneous administration in small amounts rather than a rare large dose. The schedule on this page (100 mcg starting dose, 100 to 300 mcg maintenance, up to 400 mcg upper limit over a 4 to 12 week cycle) follows that same logic: raising the dose gradually lets tolerance be assessed at each step before moving to the next level, instead of starting at the maximum. Direct clinical data on LL-37 in humans remain limited, so the figures above are a summary from public sources and protocols, not a medical recommendation and not instructions for self-administration.
This reference is research-use material. The information is not medical advice and is not intended for diagnosis, treatment or prevention of disease.